SPC
DGX icon

Stewart & Patten Company’s Quest Diagnostics DGX Stock Holding History

Stewart & Patten Company’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,906
Closed -$212K – 101
2017
Q2 		$212K Buy
+1,906
New +$202K 0.04% 99

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Stewart & Patten Company's DGX Position: Q3 2017 in Review

Stewart & Patten Company sold out of Quest Diagnostics (DGX) in Q3 2017, closing a stake of 1,906 shares — an estimated $212K sold.

Stewart & Patten Company first reported a position in DGX in Q2 2017 and held it in 1 quarter. The position peaked at $212K in Q2 2017. 616 funds tracked by Wall St. Rank hold DGX as of Q3 2017.

  • Stewart & Patten Company reported no remaining Quest Diagnostics position as of Q3 2017 after selling out during the quarter.
  • Stewart & Patten Company sold 1,906 Quest Diagnostics shares in Q3 2017, an estimated $212K.
  • Stewart & Patten Company first reported a position in Quest Diagnostics in Q2 2017 and held it in 1 quarter.
  • Stewart & Patten Company's Quest Diagnostics position peaked at $212K in Q2 2017.
  • 616 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2017.

Based on Stewart & Patten Company's 13F filing for Q3 2017, filed 27 Oct 2017.